MEDIAN Technologies Release: Great Success of its Private Placement: €10 Million Raised

Sophia Antipolis, Nice (France), May 17th, 2011 - MEDIAN Technologies, the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, today announced (i) the success of its private placement and (ii) its forthcoming listing on the Alternext market of NYSE Euronext Paris. The first full trading day for the company's stock is set to be Friday May 20th, 2011. Aurel BGC acted as Sole Bookrunner and Listing Sponsor on this operation.

Details of the placement

Private placement with qualified investors

€9 976 816 million raised

Creation of 1,239,356 new shares

Pricing: €8.05

MEDIAN Technologies' three long-standing shareholders (Draper Fisher Jurvetson ePlanet Ventures (DFJ), Idinvest Partners / AGF Private Equity and Auriga Partners) broadened their commitment by contributing €2.7 million to the round of fundraising.

Details of the NYSE Alternext listing

Number of shares listed: 5 588 838

Float: 22.24%

Share listing price: €8.05

Listing sponsor: Aurel BGC

ISIN code: FR0011049824

Ticker symbol: ALMDT

Fredrik Brag, MEDIAN Technologies' Chairman and CEO, commented: "We have developed an innovative solution for oncology imaging analysis. The system is particularly well suited to resolving the issues encountered in clinical trials and has already been adopted by three of the largest pharma companies. This round of fundraising and the forthcoming IPO will provide the necessary financing for the commercialization of our solutions and services and I wish to thank the investors who have provided us with their support."

About MEDIAN Technologies

MEDIAN Technologies was founded in 2002 by Fredrik Brag (the current Chairman and CEO), Gérard Milhiet and Arnaud Butzbach. It is based at Sophia Antipolis (in the south of France) and has a subsidiary in the USA. The company currently has a staff of 40, over half of whom work in R&D.

MEDIAN Technologies offers solutions and services for diagnosing and monitoring cancer patients. It is targeting both the oncology clinical trials market (its prime market) and the patient care market.

MEDIAN Technologies collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), Chicago University and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN Technologies has been present in the market since 2007 through direct sales of its lesion management solutions and alliances with specialist cancer centers in Europe and the USA.

Since its incorporation, the company has raised about €16 million in three rounds of financing (in 2003, 2004 and 2006/7) with major internationally respected investors, including Draper Fisher Jurvetson ePlanet Ventures (DFJ) (USA), Idinvest Partners / AGF Private Equity (France), Auriga Partners (France) and the University of Chicago Hospitals (USA). MEDIAN Technologies also benefited from €2.8 million in financial support awarded to its LESIO project by OSEO (the French state innovation agency) over the period 2008-2010 and has been accredited as an "innovative company" by the agency.

For more information about MEDIAN, visit www.mediantechnologies.com.

Caroline Carmagnol

CEO

Mob: + 33 (0) 6 64 18 99 59

Tel: + 33 (0) 1 42 68 86 43

caroline@alizerp.com

Skype : caroline.carmagnol

ALIZE RP

33, rue de Surène

75008 Paris

Fax: + 33 (0) 1 42 68 06 51